The fund marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of Dec. 31 to $832 million.
Also in this issue:
RiverVest recognized as Investor of the Year
Sivan Weitzman joins RiverVest as its first CFO
Portfolio company news from Allakos, Arch Oncology, Cardialen, Mirum Pharmaceuticals, Spruce Bioscience and WUGEN